i
Important informations
Instagram
Portal
Donate now

Our researchers

Aucun résultat

Dr., Kyle T. Greenway

Kyle T. Greenway, MD, MSc, FRCPC

Psychosocial aspects of disease

Depression, Ketamine, Phenomenology, Psychedelics, Psychopharmacology, Psychotherapy, Suicide
  • Principal Investigator, Lady Davis Institute for Medical Research
  • Staff Psychiatrist, Institute of Community and Family Psychiatry, Jewish General Hospital
  • Assistant Professor, Department of Psychiatry, McGill University

Contact details

(514) 340 8222 ext. 25890
kyle.greenway@mcgill.ca

Assistant contact details

  • Julien Thibault-Levesque,
    Research Assistant
    (438) 354-1461
    julien.thibaultlevesque.ccomtl@ssss.gouv.qc.ca

Snapshot

Dr. Kyle T. Greenway conducts clinical, naturalistic, and fundamental research on novel psychiatric interventions, particularly psychedelic-assisted psychotherapies for refractory depressive disorders. He leads the Ketamine-Assisted Therapy service at the Jewish General Hospital, one of only a handful of clinics in the world to offer a psychedelic therapy for severe depression in a public payer system. His work explores the impacts of extra-pharmacological factors on psychedelic and conventional psychiatric treatments, including how treatment protocols can be tailored to individuals based on their unique life experiences and cultures. Before joining McGill, Dr. Greenway completed postdoctoral studies at the world-leading Imperial College Psychedelic Research Centre, as well as the McGill Clinical Investigator Program.

Important Links :

See Dr. Kyle T. Greenway's publications on PubMed

Major Research Activities

Dr. Kyle T. Greenway is deeply interested in the ways in which psychopharmacology and psychotherapy intersect and overlap. His active projects are largely focused on treatment-resistant depression and involve ketamine, psilocybin, therapeutic processes, suicide, and cognition. Before clinical research, he conducted fundamental research in quantum chemistry and biomolecular modeling.

 

Dr. Greenway’s research focuses on:

  • Clinical mechanisms and use models of ketamine as a treatment for severe refractory depression and suicide.
  • Psychopharmacology including therapeutic, neural, and context effects.
  • Psilocybin-assisted psychotherapy, emphasizing the intersecting role of mind, brain, and culture.

Recent Publications and References